PCRX - Pacira BioSciences, Inc.
| Previous Close | 38.92 |
| Open | 38.73 |
| Bid | 28.00 x 800 |
| Ask | 47.00 x 2200 |
| Day's Range | 38.39 - 39.31 |
| 52 Week Range | 34.64 - 55.00 |
| Volume | 325,332 |
| Avg. Volume | 780,340 |
| Market Cap | 1.618B |
| Beta (3Y Monthly) | 0.59 |
| PE Ratio (TTM) | 210.00 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Simply Wall St.
Introducing Pacira BioSciences (NASDAQ:PCRX), The Stock That Slid 64% In The Last Five Years
We think intelligent long term investing is the way to go. But along the way some stocks are going to perform badly...
- Zacks
Pacira (PCRX) Down 15.3% Since Last Earnings Report: Can It Rebound?
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Simply Wall St.
Is Pacira BioSciences (NASDAQ:PCRX) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
- GuruFocus.com
5 Health Care Stocks in Gurus' Portfolios
Pacira BioSciences on the list Continue reading...
- Zacks
ASRT vs. PCRX: Which Stock Is the Better Value Option?
ASRT vs. PCRX: Which Stock Is the Better Value Option?
- GuruFocus.com
Pacira Biosciences Inc (PCRX) CEO and Chairman David M Stack Sold $503,038 of Shares
CEO and Chairman of Pacira Biosciences Inc (30-Year Financial, Insider Trades) David M Stack (insider trades) sold 12,849 shares of PCRX on 08/15/2019 at an average price of $39.15 a share. Continue reading...
- Zacks
Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates
Pacira (PCRX) rides high on both earnings and revenue beat in the second quarter of 2019. Moreover, Exparel drives year-over-year growth.
Motley FoolPacira Pharmaceuticals, Inc. (PCRX) Q2 2019 Earnings Call Transcript
PCRX earnings call for the period ending June 30, 2019.
- Zacks
Pacira (PCRX) Beats Q2 Earnings and Revenue Estimates
Pacira (PCRX) delivered earnings and revenue surprises of 20.59% and 2.80%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Pacira (PCRX) Earnings Expected to Grow: Should You Buy?
Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Should You Be Concerned About Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Historical Volatility?
If you own shares in Pacira BioSciences, Inc. (NASDAQ:PCRX) then it's worth thinking about how it contributes to the...
- Zacks Small Cap Research
DRRX: Favorable FDA Decision on POSIMIR Would Likely Mean Significant Upside to Our Model
This morning, Durect (DRRX) announced that they submitted a full response to FDA’s Complete Response Letter for POSIMIR, which Durect received in February 2014. POSIMIR is the company’s investigational post-operative pain relief depot that utilizes the company’s patented SABER technology and is intended to deliver bupivacaine to provide three days of pain relief after surgery. As a reminder DRRX submitted an NDA ((via 505(b)(2) pathway)) to FDA for POSIMIR in April 2013.
- Zacks
Pacira Gets EMA Acceptance for Pain Management Drug Exparel
The EMA authorizes Pacira's (PCRX) marketing application for Exparel (bupivacaine liposome injectable suspension) to treat postsurgical pain.
- Simply Wall St.
Is Pacira BioSciences, Inc. (NASDAQ:PCRX) Trading At A 36% Discount?
Today we will run through one way of estimating the intrinsic value of Pacira BioSciences, Inc. (NASDAQ:PCRX) by...
- Zacks
JAZZ or PCRX: Which Is the Better Value Stock Right Now?
JAZZ vs. PCRX: Which Stock Is the Better Value Option?
- Markit
See what the IHS Markit Score report has to say about Pacira Biosciences Inc.
Pacira Biosciences Inc NASDAQ/NGS:PCRXView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for PCRX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding PCRX are favorable, with net inflows of $2.36 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Insider Monkey
Here’s What Hedge Funds Think About Pacira Pharmaceuticals Inc (PCRX)
The government requires hedge funds and wealthy investors that crossed the $100 million equity holdings threshold are required to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings level the playing field for ordinary investors. The latest round of 13F filings disclosed the […]
- Zacks
Why Is Pacira (PCRX) Down 7.2% Since Last Earnings Report?
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Cara Shares Up on Positive Phase III Data for Itchiness Drug
Cara (CARA) reports positive top-line data from phase III study of Korsuva injection in hemodialysis patients with moderate-to-severe chronic kidney disease-related pruritus.
- Simply Wall St.
How Financially Strong Is Pacira BioSciences, Inc. (NASDAQ:PCRX)?
Pacira BioSciences, Inc. (NASDAQ:PCRX) is a small-cap stock with a market capitalization of US$1.8b. While investors...
